C12P19/60

Method for Producing Long-chain Glycosylated Genistein
20210108182 · 2021-04-15 ·

The disclosure discloses a method for producing long-chain glycosylated genistein and belongs to the technical fields of enzyme engineering and fermentation engineering. The disclosure provides a method for producing long-chain glycosylated genistein. By using this method to produce long-chain glycosylated genistein, the content of long-chain glycosylated genistein in a reaction solution and the ratio of the content of long-chain glycosylated genistein in the reaction solution to the content of total glycosylated genistein in the reaction solution can be increased. The content of long-chain glycosylated genistein in the reaction solution can be increased to 10.3 g/L, and the ratio of the content of long-chain glycosylated genistein in the reaction solution to the content of total glycosylated genistein in the reaction solution can be increased to 70%.

Method for Producing Long-chain Glycosylated Genistein
20210108182 · 2021-04-15 ·

The disclosure discloses a method for producing long-chain glycosylated genistein and belongs to the technical fields of enzyme engineering and fermentation engineering. The disclosure provides a method for producing long-chain glycosylated genistein. By using this method to produce long-chain glycosylated genistein, the content of long-chain glycosylated genistein in a reaction solution and the ratio of the content of long-chain glycosylated genistein in the reaction solution to the content of total glycosylated genistein in the reaction solution can be increased. The content of long-chain glycosylated genistein in the reaction solution can be increased to 10.3 g/L, and the ratio of the content of long-chain glycosylated genistein in the reaction solution to the content of total glycosylated genistein in the reaction solution can be increased to 70%.

MICROBIAL PRODUCTION OF TRITERPENOIDS INCLUDING MOGROSIDES

The present invention provides host cells and methods for making mogrol glycosides, including Mogroside V (Mog. V), Mogroside VI (Mog. VI), Iso-Mogroside V (Isomog. V), and glycosylation products that are minor products in Siraitia grosvenorii. The invention provides engineered enzymes and engineered host cells for producing mogrol glycosylation products, such as Mog, V. Mog. VI, and Isomog. V, at high purity and/or yield. The present technology further provides methods of making products containing mogrol glycosides, such as Mog. V, Mog. VI, and Isomog. V, including food products, beverages, oral care products, sweeteners, and flavoring products.

MICROBIAL PRODUCTION OF TRITERPENOIDS INCLUDING MOGROSIDES

The present invention provides host cells and methods for making mogrol glycosides, including Mogroside V (Mog. V), Mogroside VI (Mog. VI), Iso-Mogroside V (Isomog. V), and glycosylation products that are minor products in Siraitia grosvenorii. The invention provides engineered enzymes and engineered host cells for producing mogrol glycosylation products, such as Mog, V. Mog. VI, and Isomog. V, at high purity and/or yield. The present technology further provides methods of making products containing mogrol glycosides, such as Mog. V, Mog. VI, and Isomog. V, including food products, beverages, oral care products, sweeteners, and flavoring products.

DEVELOPMENT OF TECHNOLOGY FOR INDUCING OVER-EXPRESSION OF β-AGARASE DAGA ENZYME
20210024939 · 2021-01-28 ·

The present invention relates to a Streptomyces mutant strain in which a -agarase DagA enzyme is over-expressed and a method for developing the strain. In addition, the present invention relates to a method for producing neoagarohexaose or neoagarotetraose in vivo by using the Streptomyces mutant strain.

DEVELOPMENT OF TECHNOLOGY FOR INDUCING OVER-EXPRESSION OF β-AGARASE DAGA ENZYME
20210024939 · 2021-01-28 ·

The present invention relates to a Streptomyces mutant strain in which a -agarase DagA enzyme is over-expressed and a method for developing the strain. In addition, the present invention relates to a method for producing neoagarohexaose or neoagarotetraose in vivo by using the Streptomyces mutant strain.

Post fermented tea-derived kaempferol-based compound

The present specification relates to a novel compound separated from post fermented tea, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, the compound being capable of being widely used in post fermented tea-related industries and various fields in which the compound may be used.

Post fermented tea-derived kaempferol-based compound

The present specification relates to a novel compound separated from post fermented tea, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, the compound being capable of being widely used in post fermented tea-related industries and various fields in which the compound may be used.

Preparation and application of cyclodextrin glucosyltransferase mutant

The present invention relates to preparation and application of a cyclodextrin glucosyltransferase mutant, belonging to the fields of gene engineering and enzyme engineering. By mutating amino acids of cyclodextrin glucosyltransferase, the enzyme activity of the obtained mutant can reach 2.5 times that of wild enzyme. In addition, the cyclodextrin glucosyltransferase mutant obtained in the present invention is simple in purification and suitable for industrial production.

Preparation and application of cyclodextrin glucosyltransferase mutant

The present invention relates to preparation and application of a cyclodextrin glucosyltransferase mutant, belonging to the fields of gene engineering and enzyme engineering. By mutating amino acids of cyclodextrin glucosyltransferase, the enzyme activity of the obtained mutant can reach 2.5 times that of wild enzyme. In addition, the cyclodextrin glucosyltransferase mutant obtained in the present invention is simple in purification and suitable for industrial production.